Trial Profile
A Phase II Multicenter Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy, Followed by High-dose Therapy With Melphalan and Autologous Peripheral Blood Stem Cell Transplantation, Consolidation With KRd, and Maintenance With Lenalidomide and Dexamethasone in Patients ≤ 70 Years Old With Smoldering Multiple Myeloma (SMM) With High Risk of Progression to Symptomatic Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- Acronyms GEM-CESAR
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 A machine learning model to predict undetectable MRD in newly-diagnosed transplant-eligible MM patients was developed using the training (n=152) and internal validation cohort (n=60) consisted of 212 active MM patients enrolled in the GEM2012MENOS65 trial. The external validation cohort was defined by 66 high-risk smoldering MM patients enrolled in the GEM-CESAR trial, results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results assessing the risk of progression through the achievement of sustained minimal residual disease negativity (MRD-ve) at 3 and 5 years after HDT-ASCT, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.